Third time lucky for dupilumab with PBS listing recommendation in severe AD

Patients with severe atopic dermatitis may get access to dupilumab within months following a recommendation for PBS listing by the Pharmaceutical Benefits Advisory Committee (PBAC) . At its March meeting the PBAC recommended the listing of dupilumab for the treatment of patients aged 12 years and older with severe atopic dermatitis who are inadequately controlled ...

Already a member?

Login to keep reading.

© 2021 the limbic